Analytical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Analytical Applications
Several industry experts describe applications in pharmaceutical applications, including on-line total organic carbon analysis, ultra-fast liquid chromatography, rapid microbial testing, and differential scanning calorimetry-Raman Spectroscopy.


Pharmaceutical Technology
Volume 34, pp. s36-s30

DSC–Raman spectroscopy

Kevin P. Menard, PhD, business manager of thermal analysis at PerkinElmer (Shelton, CT)

Differential scanning calorimetry (DSC) and Raman spectroscopy are well-known techniques in pharmaceutical analysis. DSC determines glass transitions, amorphous content, melting temperatures, and enthalpy and estimates the degree of crystallinity. In its fast-scanning mode, DSC also suppresses kinetic changes (i.e., polymorphism and decompositions). This allows measurements to be made before kinetic changes can occur, allowing one to determine the initial polymorphic form as well as measure melting and heat capacity on materials before they decompose. Raman spectroscopy is able to detect changes in chemical composition as well as positional and stereochemical changes in a sample; this allows it to identify specific polymorphic states. Raman spectroscopy, however, has some difficulties in measuring temperature-dependent reactions such as dehydrations and polymorphic rearrangements. These reactions are sensitive to the temperature applied, and care must be taken so that the energy added by the Raman's laser does not affect the data by causing changes in the sample temperature (1). A combination of dual furnace (i.g., power-compensated) DSC and a shuttered laser in an Eschelle Raman spectrometer were found to give minimal increases in bulk sample temperatures (2).

As a hyphenated technique, however, DSC–Raman spectroscopy works well in detecting the changes in polymorphic materials as a function of temperature (3). For example, running a sample of acetaminophen in heating showed a series of peaks corresponding to changes in polymorphic forms, but the changes in the material corresponding to those thermal events are inferred (2). For example, an endothermic peak in the DSC themogram can be a melt, a water loss, or a polymorphic change. Raman spectroscopy allows one to confirm what the transition is; the chemical and structural changes detected from the Raman spectra clarify the DSC data. Because the DSC can performed under a wide range of thermal conditions, including heating and cooling rates from 0.1 to 750 C/min, the combined techinques can be used to characterize the materials' kinetic behavior under a wide variety of conditions. For example, crystallization processes can be studied using DSC–Raman during cooling experiments. Other work has been reported on hydrates and pseudo polymorphs as measuring the reaction of materials by tracking changes in assigned bands in the Raman spectra and the energetic changes (4, 5).

DSC–Raman spectroscopy section references

1. R. Alexander et al., Proceedings of the North American Thermal Analysis Society (NATAS) Annual Conf. (Atlanta, 2008), pp. 131–136.

2. A Dennis, K. Menard, and R. Spragg, Proceedings of the Annual Technical Conf. of the Society of Plastic Engineers (Chicago, 2009), pp 647–653.

3. K. Menard et al., Am. Lab. 42 (1), 21–23 (2010).

4. N. Redman et al., Furey, , Proceedings of NATAS Annual Conf. (Albuquerque, NM, 2003), pp. 120–129;

5. A. Bigalow-Kern et al., J. ASTM, 2 (7), 42–61 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here